Deficiência de ferro na doença renal crônica
TL;DR: The inflammatory condition present in CKD interferes with the action of erythropoietin, intestinal iron absorption and iron mobilization from deposits, due to increased hepcidin concentrations.
read more
Abstract: Anemia e uma complicacao quase universal nos pacientes em estagios avancados de doenca renal cronica (DRC). Ela esta associada com maior numero de internacoes hospitalares, maior mortalidade e pior qualidade de vida dos pacientes. Ela tem varias causas, sendo deficiencia de eritropoetina e ferro as duas principais causas. A condicao inflamatoria presente na DRC interfere com a acao da eritropoetina e com a absorcao intestinal de ferro e mobilizacao de ferro dos estoques, devido ao aumento de hepcidina. A correcao parcial (nao completa) da anemia promove melhores resultados nos pacientes com DRC.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia.
TL;DR: A review of the history, pharmacology, administration, efficacy, and safety profile of ferric carboxymaltose in the treatment of patients with iron deficiency anemia is presented in this paper.
49
Inflammation and poor response to treatment with erythropoietin in chronic kidney disease
Wander Valadares de Oliveira Júnior,Adriano de Paula Sabino,Roberta Carvalho de Figueiredo,Danyelle Romana Alves Rios +3 more
TL;DR: The aim of this study was to review the association of erythropoietin resistance and chronic inflammatory process in patients with chronic renal disease.
Artigos de tema livre / free themed articles
Secretaria Municipal de Saúde,Correspondência,Corrrespondence,Jenifer Andreia,Nascimento de Oliveira +4 more
- 01 Jan 2016
TL;DR: In this paper, an ensaio busca levantar elementos de discussao a respeito de estrategias de politicas publicas for o atendimento das necessidades alimentares especiais no ambiente escolar, a luz da interdisciplinaridade das ciencias da Nutricao e da Bioetica, na perspectiva da seguranca alimentar e nutricional e do direito humano a alimentacao adequada.
Guarana (Paullinia cupana) presents a safe and effective anti-fatigue profile in patients with chronic kidney disease: A randomized, double-blind, three-arm, controlled clinical trial
Ieda Maria Pedroso Dorneles,Mateus Batista Fucks,Paula Caitano Fontela,Matias Nunes Frizzo,Eliane Roseli Winkelmann +4 more
TL;DR: Guarana, especially at a dosage of 200 mg/day, is safe and effective in improving clinical symptoms and maintaining hemoglobin and hematocrit values.
13
Anemia in chronic kidney disease in a Hospital in the Northwest region to the State of Rio Grande do Sul
TL;DR: After the introduction of treatment for anemia occurred increased plasma levels of hemoglobin and clinical improvement, even though not having a complete normalization of these levels.
References
Anemia of Chronic Disease
TL;DR: Advances in knowledge of the causes and management of the anemia of chronic disease are discussed.
3.6K
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Ajay K. Singh,Lynda A. Szczech,Kezhen L. Tang,Huiman X. Barnhart,Shelly Sapp,Marsha Wolfson,Donal N. Reddan,Abstr Act +7 more
TL;DR: The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g perDeciliter) was associated with increased risk and no incremental improvement in the quality of life and the use of epoetin alfa targeted to achieve a level of 11.4 g perdeciliter was not associated with an increased risk.
2.7K
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Tilman B. Drüeke,Francesco Locatelli,Naomi Clyne,Kai-Uwe Eckardt,Iain C. Macdougall,Dimitrios Tsakiris,Hans-Ulrich Burger,Armin Scherhag +7 more
TL;DR: In patients with chronic kidney disease, early complete correction of anemia does not reduce the risk of cardiovascular events and there was no significant difference in the combined incidence of adverse events between the two groups.
2.1K
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer,Emmanuel A. Burdmann,Chao-Yin Chen,Mark E. Cooper,Dick de Zeeuw,Kai-Uwe Eckardt,Jan Feyzi,Peter Ivanovich,Reshma Kewalramani,Andrew S. Levey,Eldrin F. Lewis,Janet B. McGill,John J.V. McMurray,Patrick S. Parfrey,Hans-Henrik Parving,Hans-Henrik Parving,Giuseppe Remuzzi,Ajay K. Singh,Scott D. Solomon,Robert D. Toto +19 more
TL;DR: The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event ordeath or a renal event) and was associated with an increased risk of stroke.
1.9K
Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study.
Jerome L. Abramson,Claudine Jurkovitz,Viola Vaccarino,William S. Weintraub,William M. McClellan +4 more
TL;DR: Among middle-aged, community-based persons, the combination of CKD and anemia was associated with a substantial increase in stroke risk, independent of other known risk factors for stroke.
322